Preclinical Videos

  1. Validation And Trust Are The Biggest Barriers To Organ On Chip Adoption 5/19/2026

    In a live audience poll, 46% of respondents cited validation and trust as the biggest barriers to broader organ‑on‑chip adoption. The result suggests the technology itself is no longer the main hurdle; instead, confidence in reproducibility, benchmarking, and fit‑for‑purpose use will determine how quickly these models are integrated into drug discovery decision‑making.

  2. Why Women's Health Is A Breakthrough Use Case For Organ Chips 5/19/2026

    Women’s health research highlights both the limitations of traditional models and the strengths of organ‑on‑chip systems. Panelists describe how hormone dynamics, immune signaling, microbiomes, and sex‑specific biology can be studied with unprecedented precision, enabling mechanistic insights that were previously inaccessible and opening new paths beyond symptom‑based treatment.

  3. Where Organ On Chips Will Add The Most Value In 3–5 Years 5/19/2026

    Panelists emphasized that CROs and CDMOs will be essential to scaling organ on chip adoption, but only if they commit to standardized, commercial execution rather than treating these systems as experimental add ons. As Don Ingber put it plainly, CROs “need to start buying these commercial systems and start scaling” them to make organ on chip studies operationally viable for industry.

  4. The Reality Of Human On A Chip Systems 5/19/2026

    Whole‑body human‑on‑chip platforms are technically feasible, but panelists caution against viewing them as near‑term solutions for drug development. Instead, progress is being driven by strategically linked organ systems designed to answer specific biological questions—often supported by computational modeling to manage complexity.

  5. Is Organ On Chip Hype Helping Or Hurting The Field? 5/19/2026

    Linda Griffith, MIT biological engineering professor and pioneer in tissue engineering, and Don Ingber, founding director of the Wyss Institute and leading architect of organ‑on‑chip systems, dissect the role of hype in new approach methodologies—where it drives adoption, and where it risks eroding trust.

  6. How FDA Policy And NCATS Are Supporting Organs On Chips 5/19/2026

    Christine Happle explains how FDA and NIH efforts are converging to move organ‑on‑chip and microphysiological systems from innovation toward regulatory credibility. She outlines how FDA has clarified expectations for new approach methodologies (NAMs) through structured qualification pathways, most notably the ISTAND program, which has now become a permanent mechanism for evaluating non‑animal methods within a defined context of use.

  7. Using Full DEL Data To Improve Early Compound Decisions 4/29/2026

    High-throughput screens hold insights beyond individual hits. Examine a broader view of screening data that reveals structure–function patterns to guide smarter compound prioritization.

  8. Why Requalify? 4/14/2026

    Qualification is not a one-and-done activity in regulated environments. Learn when requalification is required and how lifecycle-based testing helps ensure equipment performance and compliance.

  9. OptiRun Connect: Faster Support To Minimize Downtime 4/7/2026

    Real-time monitoring and rapid support help detect issues early and keep critical equipment performing reliably. See how proactive alerts enable faster resolution and more efficient operations.

  10. My Equipment: Online Portal For Repair Requests And Service History 4/7/2026

    Manage equipment and service information in one place, submit requests from any device, review service history at a glance, and see real-time coverage details to support faster decisions.